The Latest News
-
Cancer
Endeavor Biomedicines licenses ULK1/2 inhibitor from Sanford Burnham Prebys and the Salk Institute
The exclusive agreement with Endeavor Biomedicines is for an intellectual property portfolio relating to cancer therapeutics and diagnostics that target ULK1/2, a protein involved in cell recycling. -
RNF5 is required for AML growth. The protein could be inhibited or used as a biomarker to improve patient outcomes. -
A drug discovered in the lab of Nicholas Cosford, Ph.D., professor and deputy director of the NCI-designated Cancer Center at Sanford Burnham Prebys, has entered a Phase 1 clinical study. -
Spotlight: Helen Eckmann and Ruth Claire Black share a common history with breast cancer and a drive to serve their community. -
Drug Discovery
University of Southern California Norris Comprehensive Cancer Center announces collaborative partnership with Sanford Burnham Prebys
USC researchers will collaborate with the Institute's Prebys Center to accelerate the development of groundbreaking cancer treatments. -
Children's Health
Biomarker could help diagnosis schizophrenia at an early age
Research could lead to blood-based diagnostic test for schizophrenia. -
Study represents a scientific advance toward a targeted therapy for colitis—a chronic digestive disease caused by inflammation of the colon. -
The journal Molecular Cell recently asked Laura Martin-Sancho to share her experience working on SARS-CoV-2 during the pandemic. -
ICIS honors Carl F. Ware for his seminal and original contributions to our understanding of the role of cytokines in immunology. -
Cerecor expands pipeline of novel biologics that address immunologic and immune-oncologic targets. -
Genetic Disorders and Aging
Malene Hansen, Ph.D., receives the Irving S. Wright Award of Distinction
The award, given by the Federation for Aging Research (AFAR), recognizes exceptional contributions to basic or clinical research in the field of aging. -
Genetic Disorders and Aging
Researchers dig deeper into how cells transport their waste for recycling
Findings may have important implications for understanding age-related diseases.
Living History
NCI-Designated Cancer Center
Earning the NCI designation in 1981 — just five years after its modest start in downtown La Jolla — our Cancer Center truly is "the miracle on Torrey Pines Mesa."
Next Generation
Victoria Blaho receives prestigious Lina M. Obeid Award
Victoria Blaho, Ph.D., assistant professor in the Immunity and Pathogenesis Program, has received the first-ever Lina M. Obeid Award for her promising research on the biology of sphingolipids.
Living History
Along the road to discovery
It was in 1979 when Eva Engvall asked Erkki Ruoslahti a question that would change their lives forever: "Wouldn't it be great to work in San Diego?"
Next Generation
Graduate student Katja Birker's research doesn't miss a beat
"There is no magic wand to cure congenital heart conditions–we have to do the research."
COVID-19 matching gift campaign
The power of investing in human health
Dinah Ruch is accelerating our COVID-19 efforts with a generous matching gift that doubles all donations dollar for dollar up to $500,000.
Our Partners in Discovery
We can't do it alone
Our annual Rare Disease Day symposium strengthens the global network of families, physicians and researchers to better understand and fight rare diseases in children.
Our Partners in Discovery
Getting to the finish line faster
Thanks to the philanthropic vision of Stuart and Karen Tanz, a unique collaboration seeks new treatments for diseases such as Alzheimer’s, dementia and Parkinson’s.
Our Partners in Discovery
New hope for autoimmune disease
Our partnership with Lilly—centered around a high degree of interaction—has already produced an immune therapy now in clinical trial.
Our Partners in Discovery
A master class in collaboration
Meet T. Denny Sanford, Conrad Prebys and Malin Burnham: three people who know we're stronger when we work together.
